Indexed with PubMed and Science Citation Index (E) 
Users online: 2440 
     Home | Feedback | Login 
About Current Issue Archive Ahead of print Search Instructions Online Submission Subscribe What's New Contact  
  Navigate here 
   Next article
   Previous article 
   Table of Contents
 Resource links
   Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
   Article in PDF (462 KB)
   Citation Manager
   Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
* Registration required (free)  

  In this article
   Article Figures
   Article Tables

 Article Access Statistics
    PDF Downloaded137    
    Comments [Add]    

Recommend this journal


Year : 2008  |  Volume : 74  |  Issue : 5  |  Page : 551

Expression of cell cycle inhibitor p27 Kip1 in nevi and melanomas

1 Department of Dermatology and Venereology, Akdeniz University School of Medicine, Antalya, Turkey
2 Department of Pathology, Akdeniz University School of Medicine, Antalya, Turkey

Correspondence Address:
Ayse Akman
Department of Dermatology and Venereology, Akdeniz University School of Medicine, 07070 Antalya
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0378-6323.44341

Rights and Permissions

How to cite this article:
Akman A, Ciftcioglu M A, Ozbey C, Alpsoy E. Expression of cell cycle inhibitor p27 Kip1 in nevi and melanomas. Indian J Dermatol Venereol Leprol 2008;74:551

How to cite this URL:
Akman A, Ciftcioglu M A, Ozbey C, Alpsoy E. Expression of cell cycle inhibitor p27 Kip1 in nevi and melanomas. Indian J Dermatol Venereol Leprol [serial online] 2008 [cited 2020 Nov 25];74:551. Available from:


Cutaneous melanoma, the most aggressive skin tumor, is characterized by a multifactorial etiology. [1] Multiple genetic alterations including oncogens, tumor suppressor genes, and apoptosis-related genes can cause conversion of normal cells to cancer cells. [2] It has been suggested that proliferation and progression of cancer cells relate to abnormalities in various cell cycle regulators. Cell cycle is controlled by the regulators such as cyclins, cyclin-dependent kinases, and their inhibitors. P27 Kip1 is an important cyclin-dependent kinase inhibitor. It has crucial roles in cellular processes, which cause G1 arrest when overexpressed; and it functions as a tumor suppressor. [3]

There are conflicted data of p27 Kip1 expression in melanoma and dysplastic nevi. Besides low levels of p27 Kip1 , normal levels have also been reported to be associated with melanoma. [3] The aim of the present study was to investigate the expression of p27 Kip1 in melanocyctic lesions, and to identify its possible participation in melanoma progression.

Paraffin-embedded archival tissues from 45 patients with benign nevi (14), dysplastic nevi (15), and melanoma (16) diagnosed between 1991 and 2007 were evaluated for expression of p27 Kip1 by immunohistochemistry. Medical records were reviewed for each case for demographic data, as well as clinical and pathologic characteristics. All the samples were evaluated by the same pathologist, and strong nuclear staining was accepted as positive. In every sample, 10 fields were taken and 500 cells were evaluated for each field (40x). For every field, mean values were calculated for positive nuclear stained cells. Differences of P27 Kip1 expression between groups were evaluated by nonparametric test (Mann-Whitney U test). A value of P < 0.05 was considered significant.

Sixteen unrelated patients (6 women, 10 men; mean±SD age, 55.56±16.35 years) with melanoma; 15 patients (8 women, 7 men; mean±SD age, 36.73±7.71 years) with dysplastic nevi; and 14 patients (7 women, 7 men; mean±SD age, 28.71±6.79 years) with benign nevi were enrolled in the study. Expression of p27 Kip1 as the number of positive nuclei was 454.46±26.6 (91%) for the benign nevi, 452±21.7 (90.6%) for the dysplastic nevi, and 313±42.8 (62.6%) for the melanomas [Figure 1A],[Figure 1B]. A significant difference was observed in expression of p27 Kip1 between benign nevi and melanomas ( P < 0.001). There was also a significant difference in expression of p27 Kip1 between dysplastic nevi and melanomas ( P < 0.001) [Table 1]. In melanoma cases, when the p27 Kip1 expression was analyzed according to the clinical and pathological features, it was seen that the expression was decreased in patients with metastasis, ulceration, increased tumor thickness, and male sex. But none of these changes were statistically significantly [Table 2].

In the present study we found that p27 Kip1 expression was significantly lower in melanoma patients compared to patients with benign nevi and dysplastic nevi. Morgan et al, analyzed p27 Kip1 expression in 63 melanocyctic lesions (21 Spitz nevi, 21 compound nevi, and 21 melanomas). [4] They did not report any difference in p27 Kip1 staining. On the other hand, Ivan et al, also examined p27 Kip1 protein levels in melanocytic lesions (15 nevi, 18 dysplastic nevi, and 15 melanomas), and they reported lower expression levels of p27 Kip1 in melanoma cases. In agreement with this report for benign and dysplastic nevi, we found that p27 Kip1 was highly expressed in these lesions, supporting the notion that one important function of p27 Kip1 may be to regulate stillness in nevi cells. The level of p27 Kip1 has been shown to be regulated primarily at the post-transcriptional level through the ubiquitin-proteasome-mediated pathway. [5] The low level of p27 Kip1 in cancers is suggested to be due to an enhancement of its degradation and decreased stability. [3] A potential role of the extracellular matrix has also been proposed for inducing p27 Kip1 degradation in melanoma. [6]

Melanoma cell proliferation is an important parameter in determining the biological behavior of melanoma. p27 Kip1 has been suggested to have functions related to cell adhesion and may play a role in tumor invasion and metastasis by allowing cells to escape from the primary site. Florenes et al, have shown lower p27 Kip1 expression in thicker lesions in cases with nodular melanomas. In addition, they found that patients having tumors with fewer than 5% p27 Kip1 staining cells had a significantly higher risk of early relapse of their disease compared with those expressing moderate or high levels. [7]

Our results suggest that p27 Kip1 could play a critical role in the genesis and progression of melanoma, and future studies will be required to determine therapeutic importance of p27 Kip1 , in addition to the prognostic value.

  References Top

1.Pinarbasi A, Savas B, Ciftcioglu MA, Alpsoy E. Cutaneous melanoma cases observed in Antalya from 1994 to 2003: Clinical and demographical properties. J Eur Acad Dermatol Venereol 2006;20:620-1.  Back to cited text no. 1  [PUBMED]  [FULLTEXT]
2.Zhang H, Rosdahl I. Expression of oncogenes, tumor suppressor, mismatch repair and apoptosis-related genes in primary and metastatic melanoma cells. Int J Oncol 2001;19:1149-53.  Back to cited text no. 2  [PUBMED]  
3.Ivan D, Diwan AH, Esteva FJ, Prieto VG. Expression of cell cycle inhibitor p27(Kip1) and its activator Jab1 in melanocytic lesions. Mod Pathol 2004;17:811-18.  Back to cited text no. 3  [PUBMED]  [FULLTEXT]
4.Morgan MB, Cowper SE. Expression of p-27 (kip1) in nevi and melanomas. Am J Dermatopathol 1999;21:121-4.  Back to cited text no. 4  [PUBMED]  [FULLTEXT]
5.Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V, et al . Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995;269:682-5.  Back to cited text no. 5    
6.Henriet P, Zhong ZD, Brooks PC, Weinberg KI, DeClerck YA. Contact with fibrillar collagen inhibits melanoma cell proliferation by up-regulating p27KIP1. Proc Natl Acad Sci USA 2000;97:10026-31.   Back to cited text no. 6  [PUBMED]  [FULLTEXT]
7.Florenes VA, Maelandsmo GM, Kerbel RS, Slingerland JM, Nesland JM, Holm R. Protein expression of the cell-cycle inhibitor p27Kip1 in malignant melanoma. Am J Pathol 1998;153:305-12.  Back to cited text no. 7    


  [Figure 1A], [Figure 1B]

  [Table 1], [Table 2]


Print this article  Email this article
Previous article Next article


Online since 15th March '04
Published by Wolters Kluwer - Medknow